Three insights:
1. IDCT’s safety and efficacy will be evaluated in 60 participants with single-level, mild to moderate lumbar degenerative disc disease.
2. The Phase 1/2 clinical trial aims to show IDCT’s ability to reduce inflammation and restore disc height.
3. The prospective, randomized trial will take place at 14 centers in 12 states.
More articles on devices:
Rothman Orthopaedics surgeon to lead orthopedic oncology program
New Southeastern Spine Institute moves closer to completion
Kevin Lobo’s 8+ years as Stryker CEO: Leading 20+ acquisitions, boosting robotics & more
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.